Based on the pharmacokinetics of the influenza, purified antigen vaccine, there are no conceivable porphyrinogenic effects.

Components of influenza virus type A and B.

The influenza, purified antigen vaccine is indicated in adults and children from 6 months of age for prophylaxis of influenza, especially in those who run an increased risk of associated complications. It is administered by a single intramuscular or deep subcutaneous injection.

The influenza vaccine is not metabolized by the cytochrome P450 system.

Uneventful use reported in 5 patients with acute porphyria. One report of a possible acute porphyric attack in a susceptible female with AIP, but the attack was poorly documented and several other factors could explain the symptoms. This report has therefore not been taken into account in the judgement of the porphyrinogenicity of the influenza, purified antigen vaccine.